Close Menu

NEW YORK – In the oncology field, there has been much focus on understanding the role of tumor mutational burden as a predictive biomarker for immunotherapy amid conflicting findings.

Now, in a study published last week in Nature Communications, a group of researchers has found that two major components of the immunoproteasome are associated with survival in melanoma patients and response to checkpoint inhibitors.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.